



GIG
CYMRU
NHS
WALES

Cyd-bwyllgor
Comisiynu
Joint Commissioning
Committee

Positron Emission Tomography (PET)

Commissioning Policy: CP50

Document Information	
Document Name	Positron Emission Tomography (PET)
Document No	CP50
Document Purpose	Commissioning Policy
Publication Date	August 2026
Version No	11.0
Commissioning Team Author	Cancer and Blood
Target Audience	Chief Executives, Medical Directors, Directors of Finance, Directors of Planning, Directors of Therapies, Public Health Wales, Chief Pharmacists, Service Providers, Lead Clinicians, The Wales Cancer Network, Consultant Clinical & Medical Oncologists, Service Managers of NHS Wales and, Community Health Councils, RCGP in Wales, AWPET, COSC.
Description	NHS Wales will routinely commission this specialised service in accordance with the criteria described in this policy
Document Update Information	This policy is an update to the previous published commissioning policy published in 2025. New and updated indications have been included for vaginal carcinoma, vulval carcinoma, high-risk endometrial cancer, Systemic IgG4 related disease (IgG4-RD) and Carcinoma of Unknown Primary (CUP). Guidance has been updated on patients discussed in UK national MDTs, where PET imaging is suggested. Guidance on patients with metastatic Colorectal Cancer (CRC) who are being considered for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has also been updated. Indications are marked to indicate the year of the last evidence review: [2015] No change made since the original evidence review. [2018] Indications added after updated evidence review. [2019] Indications

	added after updated evidence review. [2020] Indications has been added after updated evidence review. [2021] Indications added after updated evidence review. [2022] Indications added after updated evidence review. [2023] Indications added or amended after updated evidence review. [2024] Indications added or amended after updated evidence review [2025] Indications added or amended after updated evidence review [New/Updated 2026]
--	--

Contents

Abbreviations	6
Policy Statement	7
Welsh Language	7
Decarbonisation	7
Disclaimer	7
1. Introduction	9
1.1 Plain Language Summary	9
1.2 Aims and Objectives	10
1.3 Epidemiology	10
1.4 What NHS Wales has decided	12
1.5 Relationship with other documents	12
2. Criteria for Commissioning	15
Referral Criteria	15
Criteria for Treatment.....	15
2.1.1 Oncological Indications	15
2.1.2 Non-oncological indications	25
2.1.3 Recommendation from UK National MDT.....	27
2.2 Repeat PET/CT scans	27
2.3 Exclusion Criteria.....	27
2.4 Continuation of Treatment	27
2.5 Acceptance Criteria.....	27
2.6 Patient Pathway (Annex i)	28
2.7 Designated Centre	28
2.8 Exceptions	29
2.9 Clinical Outcome and Quality Measures	29
2.10 Responsibilities	29
3. Evidence	31
3.1 Date of Review	31
4. Equality Impact and Assessment.....	32
5. Listening to People	33
5.1 Complaints, Incidents and Redress Process.....	33
Annex i Codes.....	34
Annex ii Glossary	35

Contact Us..... 36

Abbreviations

AWMSG	All Wales Medicines Strategy Group
AWPET	All Wales PET Advisory Group
COSC	Clinical Oncology Sub-Committee
CT	Computed Tomography
DLBCL	Diffuse large B cell lymphoma
FDG	Fluorodeoxyglucose
FIGO	International Federation of Gynaecology and Obstetrics
IPFR	Individual Patient Funding Request
MDT	Multi-disciplinary Team
MRI	Magnetic resonance imaging
NWJCC	NHS Wales Joint Commissioning Committee
PET	Positron Emission Tomography
PET-CT	Positron Emission Tomography – Computed Tomography
SMC	Scottish Medicines Consortium
TCC	Transitional cell carcinoma
WG	Welsh Government
WSAC	Welsh Scientific Advisory Committee

Policy Statement

NHS Wales Joint Commissioning Committee (NWJCC) will commission positron emission tomography – computed tomography (PET-CT) services in accordance with the criteria outlined in this document.

In creating this document NWJCC has reviewed this clinical condition and the options for its treatment. It has considered the place of positron emission tomography – computed tomography (PET-CT) in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

Welsh Language

NWJCC is committed to treating the English and Welsh languages on the basis of equality, and endeavour to ensure commissioned services meet the requirements of the legislative framework for Welsh Language, including the [Welsh Language \(Wales\) Measure 2011](#) and the [Welsh Language Standards \(No.7\) Regulations](#) 2018.

Where a service is provided in a private facility or in a hospital outside of Wales, the provisions of the Welsh language standards do not directly apply but in recognition of its importance to the patient experience, the referring health board should ensure that wherever possible patients have access to their preferred language.

In order to facilitate this, NWJCC is committed to working closely with providers to ensure that in the absence of a Welsh speaker, written information will be offered. Where possible, links to local teams should be maintained during the period of care.

Decarbonisation

NWJCC is committed to taking assertive action to reducing the carbon footprint through mindful commissioning activities. Where possible and taking into account each individual patient's needs, services are provided closer to home, including via digital and virtual access, with a delivery chain for service provision and associated capital that reflects the NWJCC commitment.

Disclaimer

NWJCC assumes that healthcare professionals will use their clinical judgement, knowledge and expertise when deciding whether it is appropriate to apply this policy.

This policy may not be clinically appropriate for use in all situations and does not override the responsibility of healthcare professionals to make decisions appropriate to the

circumstances of the individual patient, in consultation with the patient and/or their carer or guardian, or Local Authority.

NWJCC disclaims any responsibility for damages arising out of the use or non-use of this policy.

1. Introduction

This policy has been developed for the planning and delivery of positron emission tomography – computed tomography (PET-CT) for people registered with a GP practice in Wales. This service will only be commissioned by the NHS Wales Joint Commissioning Committee (NWJCC) and applies to residents of all seven Health Boards in Wales.

This updated policy has been developed in collaboration with the All-Wales PET Advisory Group (AWPET). This Group is tasked with reviewing the evidence base for PET-CT and advising NWJCC on the introduction of new indications, ensuring that all decisions are made following a systematic review and appraisal of all the available evidence.

This policy presents an up to date summary of relevant indications for the use of PET-CT, where there is good evidence that patients will benefit from improved disease assessment resulting in altered management and improved outcomes.

The indications in this policy are divided into oncological and non-oncological and then by body site/system.

The purpose of this document is to:

- set out the circumstances under which patients will be able to access PET-CT services
- clarify the referral process and pathways
- define the clinical criteria that patients must meet in order to access treatment
- enable all patients in Wales to have equity of access to PET-CT services

1.1 Plain Language Summary

A PET-CT scan is a nuclear medicine imaging technique that produces a three dimensional image or picture of functional processes in the body. The purpose of a PET scan is to improve diagnosis and treatment planning for both cancer and non-cancer indications.

PET-CT is a non-invasive imaging technique that combines information from two different modalities. PET provides information about functional and metabolic cellular activity, while a CT scanner gives precise anatomical localisation.

The procedure involves injecting a radio-labelled tracer into the body. The radio-labelled tracer can be a sugar (glucose), an amino acid, or a vitamin. The tracer is taken up and accumulates in metabolically active cells (such as malignant cells) and emits gamma rays detected by the PET scanner to produce colour-coded images of the body demonstrating the cellular activity of both normal and malignant tissue. The CT scanner detects the X-rays emitted by the X-ray tube during exposures.

Images acquired from both PET and CT devices can be combined into a single superimposed image (PET-CT). This image provides important diagnostic information as well as assessing the effectiveness of treatment in cancer. The radio-labelled tracers are then passed out of the body in the urine or bowel movement.

1.2 Aims and Objectives

This policy aims to define the commissioning position of NWJCC on the use of positron emission tomography – computed tomography (PET-CT). It includes an up to date list of all PET-CT indications currently commissioned and funded by NWJCC for Welsh residents.

The objectives of this policy are to:

- ensure commissioning of PET-CT for Welsh residents
- ensure equitable access to PET-CT
- define criteria for people to access PET-CT
- describe evidence-based indications (see Section 2.2) that will improve disease assessment, resulting in altered management and improved outcomes.

1.3 Epidemiology

Positron emission tomography (PET) has become a central diagnostic tool in the management of patients with cancer and many other non-cancer conditions, and its role continues to evolve. PET influences clinical decision making, and there is an increasing body of high-quality evidence to demonstrate the contribution of PET to improved patient outcomes in a number of disease areas. All recent indications added to this policy in 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025 and 2026 are supported by the best available evidence.

The Welsh PET service is currently delivered across three sites: a fixed scanner in Cardiff (PETIC; since 2010), a mobile PET scanner located at Wrexham Hospital in North Wales (since 2015) and more recently, a mobile scanner at Singleton Hospital in Swansea (since 2020).

Clinical demand for PET scanning is growing worldwide, with a 7.8 year on year growth reported in England between 2022/23 and 2023/24¹. Wales is clearly realising this increase in demand with 6,775 PET scans performed in 2023-24 (PETIC – 3,475; North Wales – 1,484 and Swansea – 1,817) and 7201 scans undertaken in 24/25. This represents an increase of 6.3%. Previously an annual increase of 12.4-13% has been seen. Based on current activity, a projected 7633-8137 PET scans are expected to be performed in 2025/26, a 6-13% growth on the previous year's activity.

¹ <https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2024/11/DID-Annual-Statistical-Release-2023-24.pdf>

According to the National Cancer Research Institute there are 1.05 PET scanners per million population in England. The Royal College of Radiology recommendations suggest an allowance of approximately 1 scanner per million population. In Wales, there are currently 0.73 PET scanners per million population, which is significantly lower than the rest of the UK and many countries in Europe.

Following publication of the Imaging Statement of Intent (Welsh Government, 2018) in November 2018, the All Wales PET Advisory Group (AWPET) and the Welsh Scientific Advisory Committee (WSAC) produced a report "Positron Emission Tomography (PET) in Wales – Overview and Strategic Recommendations". One of its five key recommendations was that WHSSC (now NWJCC) should be commissioned to produce a Programme Business Case (PBC) for PET-CT capacity in Wales that considers increased demand projections, estates, staffing requirements and research for the next 10 years.

Following support and scrutiny from all Health Boards (HBs), the All Wales PET Programme Business Case (PBC) was endorsed by Welsh Government (WG) in August 2021. Subsequently, WG requested that WHSSC (now NWJCC) continue to "hold the ring" for this national Programme, with Dr Sian Lewis appointed as Programme SRO and a small Programme Management Office (PMO) set up at WHSSC (now NWJCC) to oversee and facilitate the Programme in April 2022. The Programme SRO is now Prof Iolo Doull, Medical Director, NWJCC.

The nationally directed Programme formally started in March 2022 and oversees a range of work that is focused on delivering sustainable and high-quality PET services across Wales, including four fixed, digital PET scanners. Features of the service in a business as usual end-state will show responsive demand and capacity planning, and will deliver clear quality outcomes through modern facilities, optimally configured workforce in fully accredited units and an assured supply of radiopharmaceuticals. Ultimately, this Programme will ensure that the population of Wales has equitable access to high quality PET scanning and research, in line with best practice across the UK and Europe.

Radiation dose

Patients referred for a PET-CT scan will receive a dose of radiation. The total dose is a combination of the PET emission scan dose and the CT transmission scan dose.

Scanning routinely extends from the base of brain to top of thighs unless there is a clinical reason to include imaging of the brain and/or lower limbs.

The typical injected activities for ¹⁸F labelled radiopharmaceuticals are between 150 to 400 MBq. This relates to an adult, whole-body, effective dose range of around 3–8 mSv.

The CT component of the study enables attenuation correction and anatomic localisation of the radiopharmaceutical uptake. It is usually performed without enhancement by iodinated contrast administration and at a lower dose than conventional diagnostic CT, typically equating to an approximate effective dose of 5 mSv. The CT can therefore account for a significant proportion of the combined PET-CT patient dose.

It may on occasion be deemed necessary to incorporate contrast-enhanced CT, in order to provide more detailed anatomical information. This would typically equate to an approximate effective dose of 16 mSv, although techniques such as automatic exposure control may be used to considerably reduce diagnostic CT doses (~ 8 mSv).

Accordingly, protocol-dependent effective doses arising from whole-body PET-CT scanning may be represented typically in the range of 8-24 mSv. Efforts are of course made to minimise radiation dose without compromising diagnostic quality.

The radiation burden from multiple radiological investigations can be substantial, leading to an increased risk of potentially fatal interval cancers compared with the rest of the population. Referrals for the clinical indications listed in this document are though justified as showing a sufficient net benefit to patients, considering the risks from exposure to ionising radiation.

1.4 What NHS Wales has decided

NWJCC has carefully reviewed the evidence of positron emission tomography – computed tomography (PET-CT). We have concluded that there is enough evidence to fund the use of positron emission tomography – computed tomography (PET-CT) within the criteria set out in section 2.1.

1.5 Relationship with other documents

This document should be read in conjunction with the following documents:

- **NHS Wales**
 - All Wales Policy: [Making Decisions in Individual Patient Funding requests](#) (IPFR).
- **NHS Wales Joint Commissioning Committee policies and service specifications**
 - NWJCC commissioning of the Epilepsy Surgery Programme. (Some brain FDG PET scans are performed as part of the pre-surgical evaluation of epilepsy and within the costs of the Epilepsy Surgery Programme).
 - [SS50, Positron Emission Tomography](#), Service Specification, March 2025.

- **National Institute of Health and Care Excellence (NICE) guidance**

- [Epilepsies in children, young people and adults](#), NICE Clinical Guideline (NG217) April 2022 (Updated 2025).
- [Colorectal Cancer: diagnosis and management](#), NICE Guideline (NG151). NICE, January 2020 (Updated December 2021).
- [Prostate Cancer: diagnosis and management](#), NICE Guideline (NG131), May 2019 (Updated December 2021).
- [Early and locally advanced breast cancer: diagnosis and management](#), NICE Guideline (NG101), July 2018 (Updated April 2025).
- [Myeloma: diagnosis and management](#), NICE Guideline (NG35), February 2016 (October 2018).
- [Pancreatic cancer in adults: diagnosis and management](#), NICE Guideline (NG85), February 2018.
- [Oesophago-gastric cancer: assessment and management in adults](#), NICE Guideline (NG83), January 2018 (Updated 2023).
- [Advanced Breast Cancer: diagnosis and management](#), Clinical Guideline (CG81) NICE, February 2009 (February 2025).
- [Non-Hodgkin's lymphoma: diagnosis and management](#), Clinical Guideline (NG52). NICE, July 2016.
- [Bladder cancer: diagnosis and management](#), NICE guideline (NG2), February 2015.
- [Lung Cancer: diagnosis and management](#), NICE Guideline (NG122). NICE, March 2019 (Updated March 2024).
- [Ovarian Cancer: recognition and initial management](#), NICE Clinical Guideline (CG122), April 2011 (Updated October 2023).
- [Metastatic malignant disease of unknown primary origin in adults: diagnosis and management](#), Clinical Guideline (CG104) NICE, July 2010 (updated April 2023).
- [Improving Outcomes for people with Sarcoma](#), Cancer Service Guideline (CSG9) NICE, March 2006.
- [Improving Outcomes in head and neck cancers](#), Cancer Service Guideline (CSG6) NICE, November 2004.

- **Relevant Scottish Medicine Consortium (SMC) policies**

- [PET-CT Guidelines – Scottish Clinical Imaging Network](#) Scottish Clinical Imaging Network (SCIN), NHS Scotland.
- [PET-CT Review of Indications report V2.0](#), Scottish Clinical Imaging Network (SCIN), NHS Scotland, July 2017.
- **Relevant NHS England policies**
 - [Positron Emission Tomography – Computed Tomography \(PET-CT\) Scanning \(All Ages\)](#), NHS England, Service Specification, 2024.
- **Other published documents**
 - [Evidence-based indications for the use of PET-CT in the United Kingdom, 2022](#). The Royal College of Radiologists.

2. Criteria for Commissioning

The NHS Wales Joint Commissioning Committee propose to approve funding of PET-CT in line with the criteria identified in this policy.

Referral Criteria

Clinicians are requested to consider the contents of this policy when discussing management options with patients.

It is expected that in all cases, PET-CT will influence management and that the patient will have followed the multidisciplinary team (MDT) process.

The referral for PET-CT should include the clinical review of the patient by a member of the referring MDT. The role of PET-CT in the various indications will be subject to prospective and retrospective audit by the Wales Research and Diagnostic Positron Emission Tomography Imaging Centre (PETIC) and the North Wales service on behalf of NWJCC. Enter inclusion criteria/split by disease type if necessary.

Criteria for Treatment

2.1.1 Oncological Indications

Adrenocortical carcinoma

- Assessment of selected patients with adrenocortical carcinoma being considered for invasive treatment where cross-sectional imaging is inconclusive. **[2018]**

Anal Cancer

- Staging of selected patients considered for radical treatment with equivocal imaging. **[2015]**
- Restaging of proven or strongly suspected recurrent or locally persistent anal cancer in whom radical salvage therapy is being planned. This includes prior to extensive pelvic surgery or groin node dissection. **[2022]**

Bladder and upper renal tract TCC

- Consider fluorodeoxyglucose (FDG) PET-CT for people with muscle-invasive bladder cancer or high-risk non-muscle-invasive bladder cancer before radical treatment if there are indeterminate findings on CT or MRI, or a high risk of metastatic disease (for example, T3b disease). **[2019]**
- Bladder cancer: FDG PET is indicated in cases of suspected or confirmed recurrent disease where radical salvage therapy is planned. **[2025]**

- Upper tract TCC: Assessment at staging and suspected recurrence where there are equivocal imaging findings and radical salvage therapy is planned **[2025]**

Breast Cancer

- High suspicion of disseminated breast cancer following breast MDT discussion when conventional imaging is negative or equivocal for the presence of metastases. **[2024]**

Patients at high risk for disseminated disease would include those with:

- Large tumours (e.g. >5 cm, T3 or above)
- Clinically positive axillary nodes
- Infra-clavicular, supra-clavicular or ipsilateral internal mammary lymph nodes suspected on conventional imaging
- Aggressive tumour biology
- Clinical signs, symptoms or laboratory values suggesting the presence of metastases. **[2024]**
- Brachial plexopathy when determination between treatment-induced Vs disease is required. **[2024]**
- Follow-up PET images on treatment authorised when FDG-avid metastatic disease demonstrated on PET alone and not on conventional imaging. **[2024]**
- Assessment of response to chemotherapy in patients when disease is not well demonstrated using other techniques including tumour markers. **[2018]**

Cancer of Unknown Primary (CUP)

1. Patients with histologically confirmed malignancy:
 - a. Where imaging and histopathology have failed to show a primary site and in whom radical/curative intent of management is proposed. **[Updated 2026]**
 - b. Where imaging and histopathology has failed to show a primary site of cancer, the patient is not suitable for radical targeted therapy but where the site of tumour will influence choice of systemic therapies (in patients physiologically fit, PS 0-1 and in whom the CUP MDT feel the PET will be pivotal to management). **[Updated 2026]**
2. Patients with suspected malignancy (but without histological confirmation):
 - Patients who are PS 0-1 and physiologically fit for a full range of systemic therapies but in whom the target lesion/lesions are deemed inaccessible for biopsy and in whom demonstration of the primary site would be pivotal to choice of offered systemic therapy. **[New 2026]**

Please note referrals, particularly in categories 1b and 2, should satisfy all of the following criteria:

- Recommendation should come from CUP MDT
- Conventional imaging and diagnostic investigations have been undertaken as recommended in NICE clinical guideline (2023)
- As a minimum CT TAP should have been undertaken and be negative or equivocal for a primary site
- Identification of the primary site should be viewed as pivotal to proceeding with appropriate management and best patient outcomes.
- PET offered only for the above categories and is not offered for other groups e.g- patients with SYMPTOMS of malignancy only. **[Updated 2026]**

Cervical cancer

- Staging or restaging of patients with carcinoma of the uterine cervix being considered for exenterative surgery. **[2015]**
- Staging of patients with carcinoma of the uterine cervix FIGO stage <IB2 with suspicious pelvic nodes on MRI or FIGO stage IB2-IVB with the exception of those patients with stage IVB who have disease outside of a radically-treatable radiotherapy field. **[2015]**
- Suspected recurrence of cervical or endometrial cancer where other imaging is equivocal and where there is a potential radical treatment option such as para-aortic radiotherapy or stereotactic radiotherapy for in-field lymph node recurrences. **[2015]**
- PET-CT for response assessment of locally advanced cervical cancer after chemoradiotherapy. **[2020]**

Cholangiocarcinoma

- Staging of potentially operable primary hepatobiliary malignancies (cholangiocarcinoma, gall bladder carcinoma), where the patient is fit for resection and a positive PET-CT would lead to a decision not to operate. **[2021]**

Colorectal cancer (CRC)

Selected patients with colorectal cancer at staging/first presentation

- Those with suspected liver or lung metastases which might subsequently be amenable for radical therapy/surgical removal. **[2021]**
- Patients with locally extensive tumours in whom extensive surgery for the primary tumour may subsequently be an option (for example those who might require extensive pelvic surgery). **[2021]**

- Highly selected patients being considered for radical therapy with equivocal imaging findings outside the standard surgical field. This might in particular include patients with equivocal pelvic nodes outside a standard resection margin, equivocal upper abdominal lymph nodes or other equivocal lesions e.g. bone in which characterisation would be pivotal to management. **[2021]**

In these patients there is often initial treatment with chemotherapy or radiotherapy prior to radical surgery. In this scenario it is recommended that PET is performed prior to the chemotherapy or radiotherapy treatment. **[2021]**

Known or suspected recurrence of colorectal cancer

- Restaging of proven or strongly suspected recurrent CRC in whom radical salvage therapy is being planned. This includes prior to resection of lung and liver metastases and extensive pelvic surgery. It also includes any other site of limited disease in which there is a radical salvage option either surgical, with radiotherapy or with cytoreductive surgery (CRS) +/- Hyperthermic Intraperitoneal Chemotherapy (HIPEC). **[Updated 2026]**
- Restaging of known colorectal cancer where conventional imaging has failed to show the cause of rising tumour markers. **[2021]**

Endometrial cancer

- Staging: FDG PET is recommended for all patients being considered for exenterative surgery. FDG PET is also recommended for all other patients with high-risk stage 3 or 4 endometrial cancer where there is a radical treatment option. These include patients initially thought to be early stage but found to have more advanced disease following surgical treatment. **[Updated 2026]**
- Recurrence/ restaging: FDG PET is recommended for all patients with confirmed or suspected recurrence of endometrial cancer where there is a radical treatment option including radiotherapy and radical surgery. **[Updated 2026]**

Gastric Cancer

- Staging of patients with gastric carcinoma who are suitable for radical treatment. **[2023]**

Gastrointestinal Stromal Tumours (GIST)

- Staging prior to treatment in patients who are likely to require extensive surgery +/-systemic therapy. **[2021]**
- Baseline and response assessment to systemic therapy. **[2021]**

Head and neck cancer

- To identify the primary site in patients presenting with metastatic squamous cell carcinoma in cervical lymph nodes, with no primary site identified on other imaging. **[2015]**
- To differentiate relapse from treatment effects in patients suspected to have tumour recurrence where magnetic resonance imaging (MRI) is uncertain or equivocal. **[2015]**
- As part of the initial clinical staging of patients with N3 cancer of the upper aerodigestive tract. **[2018]**
- Response assessment at 3-6 months following completion of radical chemo-radiotherapy. **[2018]**
- As part of the initial clinical staging of patients with T4 nasopharyngeal or hypopharyngeal squamous cell carcinoma. **[2018]**
- Include PET-CT imaging as part of the initial clinical staging of patients with T4 oropharyngeal cancer. **[2020]**
- PET-CT is indicated for the detection of a possible primary site of malignancy in an isolated level II, III or Va cystic neck mass (in patients aged 40 and over) that is biopsy negative on ultrasound + fine needle aspiration cytology, with no obvious primary site of malignancy on clinical examination, CT or MRI scan. Prior to referral, the patient should have been discussed in an MDT, following conventional imaging and diagnostic investigations as above. As part of the initial workup the patient should have as a minimum had flexible nasendoscopy inspection of the aerodigestive tract. **[2024]**

Lung Cancer

- Investigation of solitary pulmonary nodule in cases where a biopsy is not possible or has failed, depending on nodule size, position and CT characterisation. **[2015]**
- Investigation of patients with non-small cell lung cancer who are staged as candidates for surgery on CT, to look for involved intrathoracic lymph nodes and distant metastases. **[2015]**
- Investigation of patients with non-small cell lung cancer who are otherwise surgical candidates and have, on CT, limited N2/3 disease of uncertain pathological significance. **[2015]**
- Investigation of patients with non-small cell lung cancer who are candidates for radical radiotherapy on CT. **[2015]**
- Assessment of possible recurrent non-small cell lung cancer when radical treatment is being contemplated. **[2015]**

- PET-CT is indicated in staging of patients with small-cell lung cancer with limited disease on CT being considered for radical therapy **[2018]**
- Assessment of the extent of disease in mesothelioma prior to planned radical decortication. **[2015]**
- In patients with undiagnosed suspected malignant pleural thickening FDG PET may be considered. In these cases, there should have been at least one attempt to biopsy either percutaneously or via video-assisted thoracoscopic surgery (VATS) and this should have been unsuccessful. In these cases, following pleurodesis FDG PET has very little value. **[2025]**
- To exclude extra-thoracic disease in proven mesothelioma in patients considered for radical multimodality treatment. **[2025]**
- In patients with undiagnosed malignant looking anterior mediastinal masses (>3cm) FDG PET is indicated where radical therapy is planned and at least one attempt at biopsy has failed or biopsy deemed impossible. If histology has been performed and this shows thymic carcinoma, high grade thymoma or germ cell tumour and radical therapy is proposed then PET/CT is indicated. (if the biopsy shows a high-grade lymphoma then PET is already indicated in other areas of the policy). **[2025]**

Lymphoma

- Staging of FDG avid lymphomas (this should include follicular lymphoma and mantle cell lymphoma). **[2021]**
- Remission assessment for FDG avid lymphomas (this should include follicular lymphoma and mantle cell lymphoma) after completion of treatment using the 5 point scale (Deauville criteria). **[2021]**
- Interim assessment to guide response adapted treatment in selected patients with Hodgkin lymphoma. **[2021]**
- PET/CT is supported at interim in a small cohort of patients with DLBCL. These patients should be aged 61-80, low risk IPI 0 stage I/II with no bulk. (in these patients PET is supported after 2 cycles of R-CHOP therapy; in the case of a complete metabolic response, therapy for these patients may be safely limited to a total of 4 cycles of R-CHOP) **[2025]**
- Assessment of response to second line treatment and subsequent treatments for FDG avid lymphomas (this should include follicular lymphoma and mantle cell lymphoma where patients are candidates for autologous stem cell transplant). **[2021]**
- Staging of confirmed post-transplant lymphoproliferative disorders (PTLD). **[2021]**

- Prior to stem cell transplant to assess remission status and suitability for transplant. **[2021]**
- In patients being treated with CAR-T therapy, imaging immediately before cell reinfusion and at 3 months after cell reinfusion. **[2021]**
- To demonstrate metabolically active disease and potentially guide biopsy in cases of strongly suspected new, relapsed or transformed lymphoma when a haematology MDT (including a consultant radiologist) determines that:
 - a watchful waiting approach +/- radiological surveillance is inappropriate, **and**
 - conventional imaging has failed to confirm a suitable biopsy site.
 - This does NOT allow for the routine use of PET to assess undiagnosed masses or lymphadenopathy. The usual expectation/ practice in lymphoma is that histology should be obtained prior to PET imaging. These highly selected cases should have been reviewed in a haematology clinic prior to referral for PET imaging. **[2023]**
- For the vast majority of patients presenting with suspected lymphoma the expectation is that there will be preliminary biopsy confirmation of a high-grade lymphoma before proceeding to PET imaging. In some exceptional cases, at the discretion of the PET gatekeepers, in patients with a high clinical and imaging suspicion of high-grade lymphoma, PET imaging may proceed before histology is available. These cases will have been reviewed by a consultant haematologist, discussed in the MDT and there must be clinical urgency such that delay may cause harm to the patient. It is expected that these will be a small number of patients who are systemically unwell or have pressing issues such as airway or SVC compromise. **[2025]**

Myeloma

- FDG PET-CT should be offered to all patients with newly diagnosed multiple myeloma currently requiring active therapy who are fit for therapy with radical intent including being fit for autologous stem cell transplantation. **[2024]**
- For patients who are FDG PET positive at staging, FDG PET should be performed at 3 months following ASCT or maximal serological response to first line therapy. **[2024]**
- Baseline assessment in patients with non-secretory and oligo-secretory myeloma and patients with predominantly extramedullary myeloma as a baseline for subsequent response assessment. **[2022]**
- Assessment of patients with apparently solitary plasmacytoma to exclude other sites of disease. **[2022]**

- To assess response or suspected relapse in patients with oligo-secretory or non-secretory myeloma, patients with predominantly extramedullary disease and patients with solitary plasmacytoma. **[2022]**

Neuroendocrine tumours (Ga DOTA and/or FDG PET)

- FDG-PET: Staging or restaging of selected patients with higher grade tumours prior to treatment. **[2021]**
- Ga-DOTA: The staging of patients with neuroendocrine tumours and the assessment of suspected recurrence, following discussion at the neuroendocrine tumours MDT meeting where imaging is pivotal to patient management. **[2015]**
- Staging and response assessment of bone metastases in children with neuroblastoma who have non-MIBG avid/MIBG negative disease. **[2025]**

Oesophageal / oesophago -gastric cancer

- Staging of patients with oesophageal or oesophago-gastric cancer prior to radical treatment e.g. surgery or radical chemoradiotherapy. **[2015]**
- PET-CT for the restaging of locally advanced oesophageal and oesophagogastric junctional tumours following neoadjuvant treatment. **[2020]**
- Re-staging of patients with local recurrence of oesophageal or oesophago-gastric carcinoma who are suitable for salvage treatment following previous curative treatment. **[2023]**
- Evaluation of suspected recurrence of oesophago-gastric tumours when other imaging is negative or equivocal. **[2023]**

Prior to radical SABR in oligometastatic disease

- Prior to referral, the patient should have been discussed in an appropriately constituted MDT. **[2022]**
- Restaging of patients with cancer recurrence being considered for SABR to confirm oligometastatic status. **[2019]**
- Restaging of patients being considered for SABR with equivocal findings on other imaging modalities. **[2019]**

Other Cancer Sites

- Other cancer sites including melanoma and testicular where there is particular difficulty in staging, restaging or the assessment of possible recurrence. **[2015]**

Ovarian, fallopian tube and primary peritoneal cancer

- Detection of tumour in selected patients with ovarian, fallopian tube and primary peritoneal carcinoma who have rising CA125 levels and equivocal or negative imaging. **[2019]**
- Suspected recurrence of ovarian, fallopian tube and primary peritoneal carcinoma where other imaging is equivocal and where there is a potential radical treatment option. **[2019]**

Paraneoplastic disease

- Detection of occult primary tumour in patients with neurological non-metastatic manifestations of neoplastic disease, where imaging is negative or equivocal. **[2021]**

Parathyroid Adenomas (18F-Choline)

- 18F-Fluorocholine PET for Parathyroid tumour localisation after failed surgery or for recurrent hyperparathyroidism, where the tumour has not been found using conventional anatomical and functional techniques, including Sestamibi scans, ultrasound and 4D CT. **[2020]**

Pancreatic cancer

- People with obstructive jaundice. If the diagnosis is still unclear after pancreatic protocol CT, offer fluorodeoxyglucose-positron emission tomography/CT (FDG-PET-CT) and/or endoscopic ultrasound (EUS) with EUS-guided tissue sampling. **[2019]**
- People without jaundice who have pancreatic abnormalities on imaging. If the diagnosis is still unclear after pancreatic protocol CT, offer FDG-PET-CT and/or EUS with EUS-guided tissue sampling. **[2019]**
- Offer fluorodeoxyglucose-positron emission tomography/CT (FDG-PET-CT) to people with localised disease on CT who will be having radical cancer treatment (surgery, radiotherapy or systemic therapy). **[2019]**

Prostate Cancer (18 F-Choline PET/CT or 18F-PSMA PET)

- Staging of high-risk patients (clinical T3 or above or PSA > 20 or Gleason 8 or above) who are considered suitable for curative treatment following conventional imaging. **[2021]**
- Suspected recurrence in patients with a rapidly rising prostate-specific antigen (PSA) and negative or equivocal conventional imaging where the results would directly influence patient management. **[2021]**

Sarcoma

- Assessment of suspected malignant transformation with plexiform neurofibromas in patients with neurofibromatosis type 1. **[2018]**
- Staging of high grade sarcomas, unless already proven to have metastatic disease, especially Ewing's sarcoma, rhabdomyosarcoma, leiomyosarcoma, osteosarcoma, malignant fibrous histiocytoma, synovial sarcoma and myxoid liposarcoma. **[2018]**
- Pre-amputation in the setting of a high grade sarcoma where the detection of distant disease will alter the surgical management. **[2018]**
- To stage patients with metastatic sarcoma considered for liver, lung or other metastasectomy e.g., retroperitoneum (i.e where surgery would be morbid). **[2024]**
- Re-staging patients with suspected local recurrence where the investigation is useful in differentiating scar from recurrent tumour. **[2024]**
- Assessing tumour response to chemotherapy or radiotherapy. **[2024]**
- Staging of recurrent/progressive sarcoma where there are systemic chemotherapy options and where the treatment is potentially with curative intent. **[2025]**

Thyroid cancer

- Assessment of patients with elevated thyroglobulin levels and negative iodine scintigraphy with suspected recurrent disease. **[2018]**
- To evaluate disease in treated medullary thyroid carcinoma associated with elevated calcitonin levels with equivocal or normal cross-sectional imaging, bone and octreotide scintigraphy. **[2018]**

Vaginal cancer

- Staging: Patients being considered for exenterative surgery, chemo radiotherapy or radiotherapy with radical intent. **[Updated 2026]**
- Recurrence/restaging: Patients with confirmed or suspected recurrence where there is a radical treatment option to include exenteration or (chemo) radiotherapy with a radical intent. **[Updated 2026]**

Vulval cancer

- Staging: Patients being considered for exenterative surgery, chemo radiotherapy or radiotherapy with radical intent. **[Updated 2026]**
- Recurrence/ restaging: Patients with confirmed or suspected recurrence where there is a radical treatment option to include exenteration or (chemo) radiotherapy with a radical intent. **[Updated 2026]**

2.1.2 Non-oncological indications

Cardiac

- Referrals to Guy's and St Thomas's NHS Foundation Hospital for cardiac PET for the assessment of myocardial viability and hibernation will be considered on a named patient basis only. **[2015]**

Dementia (FDG)

- Evaluation of memory loss/neurological signs suggestive of dementia and differentiation of types of dementia in selected patients where there is diagnostic uncertainty. This includes patients with:
 - mild cognitive impairment
 - a dementia of early onset (<65 years)
 - an atypical presentation of dementia
 - multiple established psychiatric co-morbidities (depression, schizophrenia, bipolar illness, alcohol-related, learning difficulties) with co-existing and/or new-onset cognitive impairment
 - inconclusive formal neuropsychological assessment **[2021]**

Before referral for a PET the patient needs to have:

- been assessed by a dementia specialist (with appropriate neurological examination and cognitive testing performed) and been discussed by the dementia MDT
- had conventional cross-sectional imaging of the brain (i.e. at least 1 CT or MRI)
- had a negative or equivocal DaTSCAN, if a high pre-test probability of Lewy Body Dementia. **[2021]**

Epilepsy

- FDG PET is available for the pre-surgical evaluation of epilepsy, referrals come through the South Wales Epilepsy Surgery MDT. **[2021]**

Known or suspected cardiac sarcoidosis

- Assessment of activity and distribution of disease at baseline in those cases where there is diagnostic uncertainty despite conventional assessments and where treatment would be altered if ongoing cardiac inflammation is confirmed. **[2019]**
- Assessment of disease response where other measures to monitor response are unhelpful and/or in patients with disease resistant to treatment. **[2019]**

Infection and pyrexia of unknown origin (PUO)

- To identify the cause of pyrexia of unknown origin where conventional investigations have not revealed a source. **[2019]**
- Detection of site of focal infection in immunocompromised patients or problematic cases of infection. **[2019]**
- Evaluation of vascular graft or cardiac implantable device related infection in selected cases provided sufficient time has elapsed since surgery. **[2019]**

Rheumatology

- Detection of occult malignancy in Idiopathic Inflammatory Myopathies (IIMs) i.e. Polymyositis (PM), Dermatomyositis (DM) especially treatment resistant and/or with high-risk clinical phenotype, with no primary identified on conventional imaging. **[2023]**
- Detection of occult malignancy in patients with rare rheumatological conditions, such as, Relapsing Polychondritis and RS3PE² when high clinical suspicion of underlying malignancy, with no primary identified on conventional imaging. **[2023]**

Vasculitis

- Evaluation of suspected vasculitis in selected cases, where conventional imaging has proved inconclusive; for example, to determine the extent and distribution of the disease activity or to exclude underlying malignancy which may be a paraneoplastic phenomenon, resulting in atypical presentations of vasculitis. **[2019]**

Immunoglobulin G4 Related Disease (IgG4-RD)(18F-FDG)

18F-FDG PET/CT in adults with suspected or confirmed IgG4-RD:

- In patients with suspected disease in whom biopsy is inconclusive or deemed inaccessible **[New 2026]**
- In patients with confirmed disease to evaluate disease extent and or activity **[New 2026]**
- To assess treatment response to immunomodulatory therapy (e.g., steroids or rituximab) where other modalities are equivocal/ unhelpful **[New 2026]**

The use of PET-CT should be undertaken with caution and only after local specialist MDT discussion, where the PET-CT findings will likely impact clinical management. **[New 2026]**

² Remitting seronegative symmetrical synovitis with pitting oedema

2.1.3 Recommendation from UK National MDT

- Referrals for patients discussed in UK national MDTs, where PET imaging outside commissioning policy guidance is suggested and where gatekeepers feel the request is reasonable. **[New 2026]**

2.2 Repeat PET/CT scans

In general repeat PET/CT scans for the same indication are not encouraged as this is felt to be an inefficient use of limited resources. However repeat PET/CT will be supported if a patient has undergone PET/CT which shows limited disease, suitable for radical therapy, following this there have been delays such that the last PET/CT scan is not felt to be sufficiently current to plan treatment and the patient is still otherwise suitable for radical therapy. **[2024]**

- a) This clause is designed to be used only in the cases of patients undergoing radical intervention such as surgery or radiotherapy and does not apply to other PET indications (e.g. raised tumour markers).
- b) This indication is to be introduced on a pilot/trial basis with data collected on these cases by WHSCC and a prospective audit of whether these repeat scans lead to changes in management.

Treatment and clinical management plans are expected to be affected by the results of PET (including upstaging or down staging of patients). This will be subject to prospective audit.

2.3 Exclusion Criteria

PET-CT is only commissioned for those indications listed in section 2.1 and 2.2.

2.4 Continuation of Treatment

Healthcare professionals are expected to review a patient's health at regular intervals to ensure they are demonstrating an improvement to their health due to the treatment being given.

If no improvement to a patient's health has been recorded then clinical judgement on the continuation of treatment must be made by the treating healthcare professional.

2.5 Acceptance Criteria

The service outlined in this policy is for patients ordinarily resident in Wales, or otherwise the commissioning responsibility of the NHS in Wales. This excludes patients who whilst resident in Wales, are registered with a GP Practice in England, but includes patients resident in England who are registered with a GP Practice in Wales.

2.6 Patient Pathway (Annex i)

Clinicians in South East Wales (excluding Swansea Bay, Hywel Dda and West Bridgend) and parts of Mid Wales should refer their patients to the Wales Research and Diagnostic PET Imaging Centre (PETIC) Cardiff.

Clinicians in South West Wales, and parts of Mid Wales should refer their patients to the mobile PET-CT service at Singleton Hospital, Swansea.

Clinicians in North Wales and parts of Mid Wales should refer their patients to Nuclear Medicine, Wrexham Maelor Hospital, Wrexham.

The patient flow for mid Wales should generally follow the pattern for cancer referral to the north and south Wales specialist centres. Patients from mid Wales who would otherwise be referred to the Royal Shrewsbury Hospital for specialist treatment should be referred to north Wales for PET scans.

If the patient wishes to be referred to a provider outside of the agreed pathway, an IPFR should be submitted.

2.7 Designated Centre

Refer patients resident in South East Wales and parts of Mid Wales to:

- Wales Research and Diagnostic PET Imaging Centre (PETIC)
University Hospital of Wales
Heath Park
Cardiff
CF14 4XN

[Referral forms, contact details and further information on PETIC can be found on the PETIC website at [Wales Research and Diagnostic PET Imaging Centre - Cardiff University](#)]

Refer patients resident in South West Wales, and parts of Mid Wales to:

- Nuclear Medicine
Singleton Hospital
Swansea Bay University Health Board
Sketty Lane
Swansea
SA2 8QA

[Referral forms, contact details and further information can be found on the PETCT Swansea Website at: [Home Page - PETCT-Swansea.org.uk](#)]

Refer patients resident in North Wales and parts of Mid Wales to:

- Nuclear Medicine
Wrexham Maelor Hospital
Croesnewydd Road
Wrexham
LL13 7TD

2.8 Exceptions

If the patient does not meet the criteria for treatment as outlined in this policy, an Individual Patient Funding Request (IPFR) can be submitted for consideration in line with the All Wales Policy: Making Decisions on Individual Patient Funding Requests. The request will then be considered by the All Wales IPFR Panel.

If the patient wishes to be referred to a provider outside of the agreed pathway, an IPFR should be submitted.

Further information on making IPFR requests can be found at: [Individual Patient Funding Requests](#)

2.9 Clinical Outcome and Quality Measures

The Provider must work to written quality standards and provide monitoring information to the lead commissioner.

The centre must enable the patient's, carer's and advocate's informed participation and to be able to demonstrate this. Provision should be made for patients with communication difficulties and for children, teenagers and young adults.

2.10 Responsibilities

Referrers should:

- inform the patient and/or their parent or guardian that this treatment is not routinely funded outside the criteria in this policy, and
- refer via the agreed pathway.

Clinicians considering treatment should:

- discuss all alternative treatments with the patient and/or their parent or guardian;
- advise the patient and/or their parent or guardian of any side effects and risks of the potential treatment
- inform the patient and/or their parent or guardian that treatment is not routinely funded outside of the criteria in the policy, and

- confirm that there is contractual agreement with NWJCC for the treatment.

In all other circumstances an IPFR must be submitted.

3. Evidence

NWJCC is committed to regularly reviewing and updating all of its commissioning policies based upon the best available evidence of both clinical and cost effectiveness. All indications and associated evidence have been reviewed and assessed by AWPET as part of the annual call for indications.

3.1 Date of Review

This policy will be reviewed by NWJCC and the All-Wales PET Advisory Group (AWPET) on an annual basis. AWPET, a subgroup of the Clinical Oncology Sub-Committee (COSC) of the Welsh Scientific Advisory Committee (WSAC), will be asked to scrutinise any new evidence of clinical and cost effectiveness to help inform NWJCC of any change to the list of indications included in this document.

4. Equality Impact and Assessment

The Equality and Welsh Language Impact Assessment (EWLIA) process has been developed to help promote fair and equal treatment in the delivery of health services. It aims to enable NHS Wales Joint Commissioning Committee to identify and eliminate detrimental treatment caused by the adverse impact of health service policies upon groups and individuals for reasons of race, gender re-assignment, disability, sex, sexual orientation, age, religion and belief, marriage and civil partnership, pregnancy and maternity, socio-economic duty and language (Welsh).

This policy has been subjected to an EWLIA.

The Assessment demonstrates the policy is robust and there is no potential for discrimination or adverse impact. All opportunities to promote equality have been taken.

5. Listening to People

5.1 Complaints, Incidents and Redress Process

Whilst every effort has been made to ensure that decisions made under this policy are robust and appropriate for the patient group, it is acknowledged that there may be occasions when the patient or their representative are not happy with decisions made or the treatment provided.

The patient or their representative should be guided by the clinician, or the member of NHS staff with whom the concern is raised, to the appropriate arrangements for management of their concern.

If a patient or their representative is unhappy with the care provided during the treatment or the clinical decision to withdraw treatment provided under this policy, the patient and/or their representative should be guided to [Listening to People, The NHS Wales Complaints, Incidents and Redress Process – People's Guidance 2026](#). For services provided outside NHS Wales the patient or their representative should be guided to the [NHS Trust Concerns Procedure](#), with a copy of the concern being sent to NWJCC.

Annex i Codes

The list of ICD codes is indicative and is not exhaustive. Additional codes may be used for contract monitoring purposes, furthermore some codes may cover indications not included within this policy.

Code Category	Code	Description
OPCS	U10.4	Myocardial position emission tomography
OPCS	U21.3	Positron tomography NEC
OPCS	U36.2	Positron emission tomography with computed tomography NEC

Annex ii Glossary

All Wales PET Advisory Group (AWPET)

AWPET is tasked with reviewing the evidence base for PET-CT and advising NWJCC on the introduction of new indications, ensuring that all decisions are made following a systematic review and appraisal of all the available evidence. AWPET also support the national PET Programme with clinical advice and guidance.

Individual Patient Funding Request (IPFR)

An IPFR is a request to NHS Wales Joint Commissioning Committee (NWJCC) to fund an intervention, device or treatment for patients that fall outside the range of services and treatments routinely provided across Wales.

NHS Wales Joint Commissioning Committee (NWJCC)

NWJCC is a joint committee of the seven local health boards in Wales. The purpose of NWJCC is to ensure that the population of Wales has fair and equitable access to the full range of Tertiary Services. NWJCC ensures that services within our portfolio are commissioned from providers that have the appropriate experience and expertise. They ensure that these providers are able to provide a robust, high quality and sustainable services, which are safe for patients and are cost effective for NHS Wales.

Contact Us

If you have a question related to this document you can contact us using one of the methods outlined below.

If you would like this document in an alternative format and/or language, please contact us for assistance.

Email:

NWJCC consultation mailbox – NWJCC.Consultation@wales.nhs.uk

Telephone:

General Enquiries – 01443 433112

Website:

[Contact us - NHS Wales Joint Commissioning Committee](#)

Writing:

If you wish to contact the NHS Wales Joint Commissioning Committee, you can write to us at one of our locations below, we welcome correspondence in Welsh or English:

South Wales Office

Unit G1 The Willowford, Main Avenue, Treforest Industrial Estate, Pontypridd, CF37 5YL

North Wales Office

Unit 3, Media Point - Unit 3, Mold Business Park, Mold, CH7 1XY